Pharmacokinetics and dose proportionality of three Tramadol Contramid® OAD tablet strengths

Biopharmaceutics and Drug Disposition

Volumn 28, Issue 6, 2007, Pages 323-330

  Karhu, David ^a   El Jammal, Ali ^a   Dupain, Thibaut ^b   Gaulin, Delphine ^b   Bouchard, Sylvie ^a  

^a Labopharm Inc   (Canada)

^b CéMAX   (France)

Author keywords

Controlled release; Dose proportionality; Pharmacokinetics; Tramadol

Indexed keywords

CONTRAMID; TRAMADOL; UNCLASSIFIED DRUG;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SAMPLING; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NAUSEA; NORMAL HUMAN; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION; TANDEM MASS SPECTROMETRY; TIME; VOLUNTEER; VOMITING;

ADULT; ANALGESICS, OPIOID; AREA UNDER CURVE; ASPARTATE AMINOTRANSFERASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DIZZINESS; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; MALE; NAUSEA; PRURITUS; TABLETS, ENTERIC-COATED; TANDEM MASS SPECTROMETRY; TRAMADOL; VOMITING;

EID: 34548728684     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.561     Document Type: Article

References (22)

1. Raffa RB, Friderichs E, Reimann W et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993; 267: 331-340.
2. Desmeules JA, Piguet V, Collart L, Dayer P. Contribution of monoaminergic modulation to the analgesic effect of tramadol. Br J Clin Pharmacol 1996, 41: 7-12.
3. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic. J Pharmacol Exp Ther 1992; 260: 275-285.
4. Valle M, Garrido MJ, Pavon JM, Calvo, R, Troconiz IF. Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effects of main active metabolites of tramadol, (+)-O-desmethyltramadol and (-)-O-desmethyltramadol, in rats. J Pharmacol Exp Ther 2000, 293: 646-653.
5. Aronson MD. Nonsteroidal and inflammatory drugs traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Clin Ther 1997; 19: 420-432.
6. Shipton EA. Tramadol - present and future. Anaesth Intensive Care 2000, 28: 363-374.
7. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004, 43: 879-923.
8. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310.
9. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997; 20: 1512-1517.
10. Kruse W, Eggert-Kruse W, Rampmaier J, Runnebaum B, Weber E. Dosage frequency and drug-compliance behaviour - a comparative study on compliance with a medication to be taken twice or four times daily. Eur J Clin Pharmacol 1991; 41: 589-592.
11. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989, 261: 3273-3277.
12. Lenaerts V, Dumoulin Y, Mateescu MA. Controlled release of theophylline from cross-linked amylose tablets. J Controlled Release 1991; 15: 39-46.
13. Lintz W, Barth H, Osterloh G, Schmidt-Bothelt E. Bioavailability of enteral tramadol formulations. 1st communication: capsules. Arzneimittelforschung 1986; 36: 1278-1283.
14. Mongin G, Yakusevich V, Kope A et al. Efficacy and safety assessment of a novel once-daily tablet formulation of tramadol. Clin Drug Invest 2004; 24: 545-558.
15. Garrido MJ, Habre W, Rombout F, Troconiz IF. Population pharmacokinetic/ pharmacodynamic modelling of the analgesic effects of tramadol in pediatrics. Pharm Res 2006; 23: 2014-2023.
16. Bamigbade TA, Langford RM. The clinical use of tramadol hydrochloride. Pain Rev 1998; 5: 155-182.
17. Lehmann KA, Kratzenberg U, Schroeder-Bark B, Horrichs-Haermeyer G. Postoperative patient-controlled analgesia with tramadol: analgesic efficacy and minimum effective concentrations. Clin J Pain 1990; 6: 212-220.
18. Note for Guidance on Modified Release Oral and Transdermal Dosage Forms: Section II (Pharmacokinetic and Clinical Evaluation). CPMP/EWP/280/96. EMEA: London, 1999.
19. Hernandez-Lopez C, Martinez-Farnos L, Karhu D, Perez-Campos T, Rovira S, Encina G. Comparative bioavailability between two tramadol once-daily oral formulations. Methods Find Exp Clin Pharmacol 2006; 28: 1-6.
20. Malonne H, Sonet B, Streel B et al. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. Br J Clin Pharmacol 2004; 57: 270-278.
21. Lai JC, Sista S, Eradiri O. The pharmacokinetics of novel once daily tramadol hydrochloride extended release tablets in healthy subjects. Annual Meeting of the American Association of Pharmaceutical Scientists; 2003; 5(Suppl. 1): abstract no. M 1071.
22. Sonuga-Barke EJ, Swanson JM, Coghill D, DeCory HH, Hatch SJ. Efficacy of two once-daily methylphenidate formulations compared across dose levels at different times of the day: preliminary indications from a secondary analysis of the COMACS study data. BMC Psychiatry 2004; 4: 28.